Rizvi N, et al. Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial. Abstract OA04.07. WCLC 2019, 7-10 september, Barcelona, Spanje.
Durvalumab na chemoradiotherapie bij stadium III niet-kleincellig longcarcinoom
aug 2018 | Longoncologie